N Acetyl L Cysteine (NAC) is commonly used by HIV infected patients in the belief that it has positive impacts on their health and quality of life. There is also a wide body of evidence that suggests supplementation with NAC may be beneficial to those living with HIV. Funding is now being sought to undertake a six month double blind placebo controlled study of 400 people living with HIV who attend regularly for treatment at HIV clinics in the UK. The study will specifically look at supplementation effects on CD4 counts.
Study objectives: To evaluate the effects of NAC supplementation on CD4 counts on HIV patients receiving antiretroviral therapy.
Timeframe: One month to finalise study protocols, six months to collect data and three months to write up.
Design and Participants: Cross-sectional survey of probability sample of HIV-infected patients attending clinics in the UK.
Participants:
Inclusion and exclusion criteria – HIV infected patients in the UK. To be eligible people would need to be on successful HIV therapy, have a CD4 count over 100 and in stable health.
